.Attributes Medication, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- medication conjugate (ADC) tisotumab vedotin resulted in strengthened progression-free as well as overall survival, triggering FDA commendation as well as a brand-new treatment possibility for patients.